- ISIN: CH0106213793
- Land: Schweiz
Nachricht vom 16.04.2018 | 07:00
Polyphor to present data at the 28th European Congress of Clinical Microbiology
EQS Group-News: Polyphor AG / Key word(s): Study/Study results
Allschwil, Switzerland, April 16th, 2018
Polyphor today announced that the company will present data on its Outer Membrane Targeting Antibiotics (OMPTAs) and lead compound murepavadin (POL7080) at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) taking place in Madrid, Spain, from 21 – 24 April 2018.
Polyphor will deliver an oral presentation, host a symposium and give six poster presentations.
In the oral presentation, Dr Anatol Luther, Head of Chemistry, will provide an overview of the OMPTA class:
Outer membrane protein targeting antibiotics (OMPTAs): a novel class with potent activity against Gram-negative organisms including XDR and colistin-resistant isolates.
Anatol Luther, Ph.D., #O0246, April 21, 16.30 - 16.40 h (see session: New drugs and tricks against MDR bacteria)
In the seminar, Dr Glenn Dale, Head of Antibiotic Research and Early Development, Polyphor will talk on AMP mimetics:
The diversity of AMP mimetics. Glenn Dale, Ph.D., #S0919, April 24, 10.00 - 10.30 h (see session: Early antimicrobial drug development news)
In addition, Polyphor will present six posters on 23 April, 13.30 - 14.30 h (see session PS083: Membrane-active antibiotics and peptides: in vitro and in vivo activity)
Title: Murepavadin activity tested against contemporary (2016-2017) clinical isolates of extensively drug-resistant (XDR) Pseudomonas aeruginosa (#P1661)
Title: Antimicrobial activity of murepavadin tested against clinical isolates of Pseudomonas aeruginosa collected in Europe, the United States and China (#P1662)
Title: Outer membrane protein targeting antibiotics (OMPTAs): in vivo characterization of a novel class of compounds with respect to pharmacokinetics, efficacy and renal toxicity (#P1665)
Title: Outer membrane protein targeting antibiotics (OMPTAs): a novel class with potent in vitro and in vivo activity against E. coli-harbouring mcr-1 and/or mcr-3 genes (#P1666)
Title: Investigation of the in vitro time-kill kinetics and the rate of resistance development by spontaneous mutations and serial passage of murepavadin and standard-of-care antibiotics towards P. aeruginosa (#P1667)
Title: Outer membrane protein targeting antibiotics (OMPTAs): investigation of the in vitro time-kill kinetics and rate of resistance development by serial passage (#P1668)
Full abstracts will be available on the ECCMID website: http://www.eccmidlive.org/#
Dr Glenn Dale, Head of Antibiotic Research and Early Development, Polyphor, commented: “We are looking forward to attending ECCMID and providing updates on our new OMPTA class of antibiotics, the first new class of antibiotics in Phase III clinical development against Gram-negative bacteria in 50 years. We will also provide an update on our most advanced OMPTA product candidate, murepavadin, a precision medicine for the treatment of nosocomial pneumonia due to Pseudomonas aeruginosa.”
Polyphor is a clinical stage, privately held Swiss specialty pharma company which has discovered and is developing the OMPTA (Outer Membrane Protein Targeting Antibiotics). The OMPTA are potentially the first new class of antibiotics against Gram-negative bacteria to have reached phase III stage in the last 50 years. The company’s lead product, murepavadin, (POL7080) is in Phase III development against Pseudomonas aeruginosa – recognized as a critical priority 1 pathogen by WHO. Polyphor is also developing an immuno-oncology candidate, balixafortide (POL6326), which has achieved clinical proof of concept in a Phase Ib/proof of concept study in combination with eribulin in patients with advanced breast cancer, and a pipeline of further preclinical antibiotics based on its OMPTA platform. Polyphor is based in Allschwil near Basel. For more information, please visit www.polyphor.com.
For further information please contact:
Tel: +41 61 567 16 00
Chief Financial Officer
Tel: +41 61 567 16 67
Document title: Polyphor to present data at the 28th European Congress of Clinical Microbiology
GBC im Fokus
M1 Kliniken: Geschäftsjahr über den Erwartungen
Mit dem deutlichen Anstieg auf 21 Klinikstandorte (Ende 2016: 13) hat die auf ästhetische Medizin spezialisierte M1 Kliniken AG die Basis für einen Ausbau der Umsatz- und Ertragsbasis gelegt. Hinzu kommt die bereits in Umsetzung befindliche Erschließung weiterer Umsatzströme, wie etwa die Erweiterung der Eigenmarken oder die Abdeckung der ästhetischen Zahnmedizin. Das Kursziel beläuft sich auf 18,50 € und das Rating lautet KAUFEN.
Der AKTIONÄR News
21. Mai 10:00 Geliebter Beton: Die Totgesagte
20. Mai 10:00 Geliebter Beton: Die Weitsichtigen
20. Mai 09:33 Elite Defensiv Index: Eine sichere Bank
18. Mai 2018
Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index
21. Mai 2018